DES, or Diethylstilbestrol, is a transplacental endocrine-disrupting chemical. It is a synthetic non-steroidal oestrogen that was once prescribed to pregnant women, though its efficacy in preventing spontaneous abortion was unproven [1,2,3,4]. It is classified as carcinogenic to humans [1].

DES has extensive deleterious effects. It can cause abnormalities or cancers of the genital tract and breast, neurodevelopmental alterations, problems in socio-sexual behavior, and immune, pancreatic and cardiovascular disorders. It affects not only the pregnant women who took it but also their children and grandchildren. In utero exposure to DES has been shown to increase the risk of preterm delivery, congenital malformations, and certain health issues in the offspring and grandchildren [1,2]. For example, in a French study, about one-quarter of DES grandchildren were born prematurely, and cerebral palsy was more frequent in this group compared to the control group [2].

In conclusion, DES has long-lasting and far-reaching impacts on multiple generations. Its effects on pregnancy outcomes, cancer risks, and congenital health issues highlight its significance in understanding the long-term consequences of endocrine-disrupting chemicals. The study of DES-exposed individuals and their descendants provides valuable insights into the transgenerational effects of such compounds on human health [1,2,3,4].